[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 1995

Isotretinoin Treatment of Human Immunodeficiency Virus-Associated Eosinophilic FolliculitisResults of an Open, Pilot Trial

Author Affiliations

From the Department of Dermatology, Harvard Medical School, and Division of Dermatology, New England Deaconess Hospital, Boston, Mass. Dr Avram is now with the Stough Clinic, Hot Springs, Ark.

Arch Dermatol. 1995;131(9):1047-1050. doi:10.1001/archderm.1995.01690210077012

Background:  Human immunodeficiency virus-associated eosinophilic folliculitis is a pruritic eruption seen in advanced infection with human immunodeficiency virus. The associated pruritus causes considerable morbidity and is poorly responsive to conventional therapy. We studied whether isotretinoin would prove efficacious in the treatment of human immunodeficiency virus-associated eosinophilic folliculitis. Seven patients with biopsy specimen-proved human immunodeficiency virus-associated eosinophilic folliculitis were treated with a mean of 7.7 weeks of isotretinoin therapy and their responses were monitored.

Observations:  All patients responded with complete symptomatologic and clinical remission within 1 to 4 weeks of isotretinoin therapy. Four (57%) of seven patients remained in complete remission after just one course of isotretinoin therapy, while three (43%) of seven patients experienced up to three brief relapses, all rapidly responsive to further isotretinoin therapy. Patients remained free of disease for up to 9 months after therapy.

Conclusions:  Isotretinoin appears to be a promising treatment for human immunodeficiency virus-associated eosinophilic folliculitis. A double-blind, placebo-controlled trial is indicated.(Arch Dermatol. 1995;131:1047-1050)